Debra Stephanie Barker
Director/Board Member at BERGENBIO ASA
Net worth: 36 120 $ as of 2024-04-29
Debra Stephanie Barker active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BERGENBIO ASA | Director/Board Member | 2019-03-12 | - |
| DESTINY PHARMA PLC | Director/Board Member | 2019-12-31 | - |
| Independent Dir/Board Member | 2019-12-31 | - | |
| Chief Executive Officer | 2023-05-24 | 2023-08-31 | |
| Chief Tech/Sci/R&D Officer | 2023-08-31 | - | |
| CUREVAC N.V. | Director/Board Member | 2022-06-21 | - |
| ARIX BIOSCIENCE PLC | Director/Board Member | 2022-08-09 | - |
| Independent Dir/Board Member | 2022-08-09 | - | |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 2022-07-31 | - |
Career history of Debra Stephanie Barker
Former positions of Debra Stephanie Barker
| Companies | Position | Start | End |
|---|---|---|---|
| SPEXIS AG | Chief Tech/Sci/R&D Officer | 2017-04-30 | 2018-12-30 |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
Training of Debra Stephanie Barker
| King's College London | Graduate Degree |
| Queens' College Cambridge | Doctorate Degree |
Statistics
International
| United Kingdom | 6 |
| Switzerland | 4 |
| Germany | 3 |
Operational
| Director/Board Member | 7 |
| Chief Tech/Sci/R&D Officer | 2 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 3 |
| Finance | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 6 |
|---|---|
| NOVARTIS AG | Health Technology |
| SPEXIS AG | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| CUREVAC N.V. | Health Technology |
| Private companies | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |